Page 52 - GPD-3-3

Gene & Protein in Disease Phage therapy for Mycobacterium infections

glycopeptidolipid overproduction and affects surface into molecular mechanisms from persistence to virulence.
properties in Mycobacterium smegmatis. Tuberculosis J Res Med Sci. 2018;23:63.
(Edinb). 2008;88(5):390-398.
doi: 10.4103/jrms.JRMS_904_17
doi: 10.1016/j.tube.2008.02.005
69. To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V.
59. Le Moigne V, Bernut A, Cortès M, et al. Lsr2 Is an important General overview of nontuberculous mycobacteria
determinant of intracellular growth and virulence in opportunistic pathogens: Mycobacterium avium and
Mycobacterium abscessus. Front Microbiol. 2019;10:905. Mycobacterium abscessus. J Clin Med. 2020;9(8):2541.
doi: 10.3389/fmicb.2019.00905 doi: 10.3390/jcm9082541
60. Colangeli R, Haq A, Arcus VL, et al. The multifunctional 70. Kothavade RJ, Dhurat RS, Mishra SN, Kothavade UR.
histone-like protein Lsr2 protects mycobacteria against Clinical and laboratory aspects of the diagnosis and
reactive oxygen intermediates. Proc Natl Acad Sci U S A. management of cutaneous and subcutaneous infections
2009;106(11):4414-4418. caused by rapidly growing mycobacteria. Eur J Clin Microbiol
doi: 10.1073/pnas.0810126106 Infect Dis. 2013;32(2):161-188.
61. Dulberger CL, Guerrero-Bustamante CA, Owen SV, et al. doi: 10.1007/s10096-012-1766-8
Mycobacterial nucleoid-associated protein Lsr2 is required 71. Jamal F, Hammer MM. Nontuberculous mycobacterial
for productive mycobacteriophage infection. Nat Microbiol. infections. Radiol Clin North Am. 2022;60(3):399-408.
2023;8(4):695-710.
doi: 10.1016/j.rcl.2022.01.012
doi: 10.1038/s41564-023-01333-x
72. Locatelli ME, Tosto S, D’Agata V, et al. Disseminated
62. Wetzel KS, Illouz M, Abad L, et al. Mycobacterium trehalose disease by Mycobacterium abscessus and Mycobacterium
polyphleates are required for infection by therapeutically celatum in an Immunocompromised Host. Am J Case
useful mycobacteriophages BPs and Muddy. bioRxiv Rep. 2020;21:e921517.
[Preprint]. 2023.
doi: 10.12659/ajcr.921517
doi: 10.1101/2023.03.14.532567
73. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B.
63. Guidry TV, Hunter RL, Actor JK. Mycobacterial glycolipid Mycobacterium abscessus: A new antibiotic nightmare.
trehalose 6,6’-dimycolate-induced hypersensitive J Antimicrob Chemother. 2012;67(4):810-818.
granulomas: Contribution of CD4+ lymphocytes.
Microbiology (Reading). 2007;153(Pt 10):3360-3369. doi: 10.1093/jac/dkr578
doi: 10.1099/mic.0.2007/010850-0 74. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR.
Mycobacterium abscessus complex infections in humans.
64. Hurst-Hess K, Walz A, Yang Y, et al. Intrapulmonary Emerg Infect Dis. 2015;21(9):1638-1646.
treatment with mycobacteriophage LysB rapidly reduces
Mycobacterium abscessus burden. Antimicrob Agents doi: 10.3201/2109.141634
Chemother. 2023;67(6):e0016223. 75. Chen J, Zhao L, Mao Y, et al. Clinical efficacy and adverse
doi: 10.1128/aac.00162-23 effects of antibiotics used to treat Mycobacterium abscessus
pulmonary disease. Front Microbiol. 2019;10:1977.
65. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage
therapy in bacterial infections treatment: One hundred doi: 10.3389/fmicb.2019.01977
years after the discovery of bacteriophages. Curr Microbiol. 76. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al.
2017;74(2):277-283. Engineered bacteriophages for treatment of a patient with
doi: 10.1007/s00284-016-1166-x a disseminated drug-resistant Mycobacterium abscessus. Nat
Med. 2019;25(5):730-733.
66. Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z,
Dheda K. Drug-resistant tuberculosis: An update on doi: 10.1038/s41591-019-0437-z
disease burden, diagnosis and treatment. Respirology. 77. Nick JA, Dedrick RM, Gray AL, et al. Host and pathogen
2018;23(7):656-673. response to bacteriophage engineered against Mycobacterium
doi: 10.1111/resp.13304 abscessus lung infection. Cell. 2022;185(11):1860-1874.e12.
67. Meacci F, Orrù G, Iona E, et al. Drug resistance evolution doi: 10.1016/j.cell.2022.04.024
of a Mycobacterium tuberculosis strain from a noncompliant 78. Little JS, Dedrick RM, Freeman KG, et al. Bacteriophage
patient. J Clin Microbiol. 2005;43(7):3114-3120. treatment of disseminated cutaneous Mycobacterium
doi: 10.1128/jcm.43.7.3114-3120.2005 chelonae infection. Nat Commun. 2022;13(1):2313.
68. Ghazaei C. Mycobacterium tuberculosis and lipids: Insights doi: 10.1038/s41467-022-29689-4

Volume 3 Issue 3 (2024) 13 doi: 10.36922/gpd.2935